Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an oral antidiabetic medication to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, this… Read more













































Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an oral antidiabetic medication to improve glycemic control in adults with type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, this drug prolongs the activity of incretin hormones like GLP-1 and GIP, which enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner. In pharmaceutical research and development, Sitagliptin reference standards, including identified impurities, synthetic intermediates, degradation products, and stable isotope labelled compounds, are essential for rigorous quality control. Laboratories utilize these high-quality materials for impurity profiling, method development, and the validation of analytical procedures such as HPLC-based testing. These compounds are also critical for forced degradation studies and ensuring ongoing regulatory compliance, as they allow analysts to accurately identify and quantify process-related impurities and degradants to maintain the safety and efficacy of the final pharmaceutical formulation.